Higher price of Covaxin in private markets needed to sustain costs: Bharat Biotech

Supply to the government of India at ₹150 per dose is a non-competitive price and clearly not sustainable in the long run, the company said

Comments

Popular posts from this blog

Bengaluru: Bus conductor fails to return Rs 1; court orders BMTC to pay Rs 3K as compensation

Karnataka court issues summons to Yediyurappa in POCSO case

MUDA case: Karnataka HC rejects Siddaramaiah’s plea against Governor move